Stockscreener 앱 받기
3.36
1.20%
0.04
시간 외 거래:
3.36
전일 마감가:
$3.32
열려 있는:
$3.32
하루 거래량:
879.45K
Relative Volume:
0.68
시가총액:
$1.15B
수익:
$787.89M
순이익/손실:
$20.56M
주가수익비율:
57.44
EPS:
0.0585
순현금흐름:
$96.54M
1주 성능:
-1.18%
1개월 성능:
-2.33%
6개월 성능:
+64.71%
1년 성능:
-15.79%
1일 변동 폭
$3.31
$3.40
1주일 범위
$3.305
$3.455
52주 변동 폭
$1.77
$5.8099
Goodrx Holdings Inc Stock (GDRX) Company Profile
명칭
Goodrx Holdings Inc
전화
(855) 268-2822
주소
2701 OLYMPIC BOULEVARD, SANTA MONICA
Compare GDRX vs VEEV, TEM, BTSG, TXG, HNGE
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GDRX
Goodrx Holdings Inc
|
3.36 | 1.13B | 787.89M | 20.56M | 96.54M | 0.0585 |
VEEV
Veeva Systems Inc
|
274.84 | 43.84B | 3.32B | 941.65M | 1.64B | 5.6161 |
TEM
Tempus Ai Inc
|
82.24 | 13.91B | 1.36B | -302.91M | -219.93M | -1.7182 |
BTSG
Brightspring Health Services Inc
|
56.02 | 11.04B | 13.65B | 169.86M | 412.12M | 1.0758 |
TXG
10 X Genomics Inc
|
84.11 | 9.85B | 638.78M | -22.66M | 122.18M | -0.1744 |
HNGE
Hinge Health Inc
|
91.98 | 7.45B | 646.34M | -512.40M | 202.76M | -6.6871 |
Goodrx Holdings Inc Stock (GDRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-27 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2026-01-22 | 다운그레이드 | Jefferies | Buy → Hold |
| 2025-12-09 | 개시 | Barclays | Underweight |
| 2025-08-11 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2024-12-04 | 개시 | Mizuho | Neutral |
| 2024-08-09 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-05-23 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-05-16 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2024-04-10 | 업그레이드 | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2024-03-25 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-03-01 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-02-26 | 개시 | Leerink Partners | Outperform |
| 2024-01-02 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2023-08-10 | 업그레이드 | DA Davidson | Neutral → Buy |
| 2023-07-31 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2022-12-01 | 개시 | Citigroup | Buy |
| 2022-11-04 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2022-09-16 | 개시 | KeyBanc Capital Markets | Sector Weight |
| 2022-09-07 | 개시 | Truist | Hold |
| 2022-08-12 | 개시 | DA Davidson | Neutral |
| 2022-06-10 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-06-06 | 재개 | BofA Securities | Buy |
| 2022-06-01 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2022-05-10 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-05-10 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-05-10 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2022-05-10 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2022-04-11 | 개시 | Wells Fargo | Equal Weight |
| 2022-04-07 | 개시 | Guggenheim | Buy |
| 2022-04-01 | 재개 | Credit Suisse | Neutral |
| 2022-03-15 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2022-03-01 | 재확인 | Barclays | Overweight |
| 2022-03-01 | 재확인 | BofA Securities | Neutral |
| 2022-03-01 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2022-03-01 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2022-03-01 | 재확인 | Evercore ISI | Outperform |
| 2022-03-01 | 재확인 | Goldman | Buy |
| 2022-03-01 | 재확인 | JP Morgan | Underweight |
| 2022-03-01 | 재확인 | RBC Capital Mkts | Outperform |
| 2022-03-01 | 재확인 | SVB Leerink | Outperform |
| 2022-01-07 | 개시 | Goldman | Buy |
| 2021-12-21 | 개시 | Stephens | Overweight |
| 2021-12-02 | 개시 | Jefferies | Buy |
| 2021-08-31 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2021-08-13 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2021-05-28 | 개시 | Robert W. Baird | Neutral |
| 2021-04-06 | 재개 | Evercore ISI | Outperform |
| 2021-01-25 | 개시 | Guggenheim | Buy |
| 2020-11-19 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-18 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-10-19 | 개시 | Barclays | Equal Weight |
| 2020-10-19 | 개시 | BofA Securities | Neutral |
| 2020-10-19 | 개시 | Citigroup | Buy |
| 2020-10-19 | 개시 | Cowen | Outperform |
| 2020-10-19 | 개시 | Credit Suisse | Outperform |
| 2020-10-19 | 개시 | Deutsche Bank | Hold |
| 2020-10-19 | 개시 | Goldman | Neutral |
| 2020-10-19 | 개시 | JP Morgan | Neutral |
| 2020-10-19 | 개시 | Morgan Stanley | Overweight |
| 2020-10-19 | 개시 | RBC Capital Mkts | Sector Perform |
| 2020-10-19 | 개시 | SVB Leerink | Outperform |
| 2020-10-19 | 개시 | UBS | Buy |
모두보기
Goodrx Holdings Inc 주식(GDRX)의 최신 뉴스
GoodRx Holdings, Inc. (GDRX) Stock Analysis: Assessing A Potential 18.90% Upside - DirectorsTalk Interviews
Enterprise value to EBITDA forward of GoodRx Holdings, Inc. Class A – FWB:8GH - TradingView
GoodRx CFO Justin Fengler Reports RSU Vesting and Share Withholding on September 15, 2026 - Kalkine Media
GoodRx CAO Thomas Chan Reports RSU Vesting and Tax-Related Share Withholding on September 15, 2026 - Kalkine Media
BofA Securities Maintains GoodRx(GDRX.US) With Sell Rating, Maintains Target Price $2.65 - Moomoo
GoodRX’s $32 Million Data-Sharing Settlement Wins Initial Nod - Bloomberg Law News
[GDRX] Q2 2026 Earnings: EPS of $0.08 Falls Just Short of Consensus EstimatesQuarterly Financial Update - dars.gov.et
InvestingPro Fair Value delivers 64% return on GoodRx in 5 months By Investing.com - Investing.com Australia
GoodRx offers health subscription for families, to launch as employee benefit in 2027 - reuters.com
GDRX Looks 34.8% Undervalued on GF Value™ - GuruFocus
One plan covers kids, adults and pets. GoodRx's new membership costs $24.99 a month. - Stock Titan
Promising Penny Stocks To Consider In August 2026 - simplywall.st
Goodrx Holdings Inc (GDRX) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
GoodRx (NASDAQ:GDRX) 10% owner Francisco Partners sells $5.48m in stock - Investing.com India
Major GoodRx (NASDAQ: GDRX) holder reshapes stake via conversion and sale - Stock Titan
GoodRx Stock (GDRX) Opinions on TrumpRx Partnership - Moomoo
GoodRx (GDRX) Results Breakdown: The Available Scorecard Is Mostly Near Expectations in the Current Update; Share Move: Shares Close 3.09% Lower in Latest TradingROE Trend Analysis - vinanet.vn
GoodRx (GDRX) Q2 2026 Earnings Call Transcript - AOL.com
GDRX Maintains Underweight Rating -- Price Target Raised to $4.0 - GuruFocus
Q2 2026 GoodRx Holdings, Inc. Earnings Call Transcript - GuruFocus
Justin Fengler Net Worth (2026) - GuruFocus
Big GoodRx (NASDAQ: GDRX) backer prepares share sale - Stock Titan
Technology Crossover Management X Ltd. Buys Shares of 1,653,566 GoodRx Holdings, Inc. $GDRX - MarketBeat
GoodRx (GDRX) Results at a Glance: The Available Figures Are Largely Near Expectations at the Close; Stock Move - vinanet.vn
GoodRx (GDRX) Results at a Glance: The Available Figures Are Largely Near Expectations at the Close; Stock Move: Shares Move Lower 1.88% in Latest TradingTrough Earnings Signal - dars.gov.et
GoodRx Holdings Inc (GDRX) (Q2 2026) Earnings Call Highlights: R - GuruFocus
GoodRx (NASDAQ:GDRX) Rating Increased to Buy at Wall Street Zen - MarketBeat
Reflecting On Healthcare Technology Stocks’ Q2 Earnings: GoodRx (NASDAQ:GDRX) - Yahoo Finance
GoodRx Holdings, Inc. (NASDAQ:GDRX) Receives Average Rating of "Hold" from Brokerages - MarketBeat
GDRX Maintained by UBS -- Price Target Raised to $3.75 - GuruFocus
GoodRx (GDRX) Stock Looks Overvalued On Its Earnings Outlook - Yahoo Finance
GoodRx Holdings (GDRX) Could Be 13% Overvalued After Q2 Earnings and Guidance Raise - Yahoo Finance
GoodRx (NASDAQ:GDRX) Trading Down 5.1%What's Next? - MarketBeat
GoodRx: Direct Brand Launches And New Subscription Plans Are Offering Hope (NASDAQ:GDRX) - Seeking Alpha
GDRX Maintained by Citigroup -- Price Target Raised to $5.00 - GuruFocus
GoodRx (NASDAQ:GDRX) Stock Price Expected to Rise, Citigroup Analyst Says - MarketBeat
GDRX Maintained by TD Cowen -- Price Target Raised to $5.00 - GuruFocus
GDRX Q2 Deep Dive: Pharma Direct and Subscription Growth Drive Upgraded Outlook - finance.yahoo.com
GOODRX HOLDINGS, INC. : CITIGROUP RAISES TARGET PRICE TO $5 FROM $4 - Bitget
GDRX Maintains Overweight by Wells Fargo -- Price Target Raised to $5.00 - GuruFocus
GoodRx Holdings Price Target Raised to $5.00/Share From $3.50 by Wells Fargo - Moomoo
Prescription savings giant GoodRx could be opening office at The Pearl - The Business Journals
GoodRx Holdings Inc (GDRX) Stock Analysis & Forecast - TradingKey
GoodRx Holdings Inc (GDRX) Stock News Today - TradingKey
Wells Fargo & Company Boosts GoodRx (NASDAQ:GDRX) Price Target to $5.00 - MarketBeat
GoodRx Holdings Inc (GDRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
GoodRx Holdings, Inc. Stock 12‑Month Price Target Raised to $3.7 - TradingView
Morgan Stanley Adjusts Price Target on GoodRx to $4 From $3, Maintains Equalweight Rating - marketscreener.com
Goodrx Holdings Inc (GDRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.07%
2.68%
자본화:
|
볼륨(24시간):